Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy

Dirk Wildemeersch, E. Schacht, P. Wildemeersch, K Calleweart, Kris Pylyser, N De Wever
In: Maturitas · 2003 · vol. 48(1) , pp. 65–70 · doi:10.1016/j.maturitas.2003.07.002 · PMID:15223110 · W2047724301
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-19 ⓘ

This 3-year trial demonstrated that a low-dose levonorgestrel-releasing intrauterine system effectively suppressed endometrial proliferation in postmenopausal women undergoing estrogen substitution therapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo evaluate the pharmacodynamic effects of a novel intrauterine drug delivery system, FibroPlant-levonorgestrel (LNG), on the endometrium in 24 postmenopausal women using estrogen substitution therapy (EST) to suppress climacteric symptoms.DesignA 3-year non-comparative prospective clinical trial.SubjectsThe treatment with the FibroPlant-LNG intrauterine system (IUS), releasing 14 microg of LNG per day, was part of a regimen for estrogen substitution therapy in symptomatic postmenopausal women to prevent endometrial proliferation and bleeding. The majority of women received percutaneous 17 beta estradiol, 1.5 mg daily, or an equivalent dose by patch or orally, on a continuous basis.Outcome measuresMenstrual pattern, endometrial histology and ultrasonographic evidence of endometrial suppression, after 3 years of use.ResultsThe endometrial histology specimen showed profound endometrial suppression with glandular atrophy and stroma decidualization in all women. On transvaginal ultrasound, this corresponds with a thin endometrium (<5 mm) and clinically with a "bleed-free" menstrual pattern or amenorrhoea.ConclusionThe results of this 3-year study in 24 postmenopausal women using EST suggest that the FibroPlant-LNG IUS is effective in causing strong suppression of the endometrium during the entire period of EST. Target delivery in the uterine cavity could be the preferred route of administering a progestin to oppose estrogen stimulation of the endometrium.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (2)

References (30)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-11T06:21:44.532445+00:00
unpaywall
last seen: 2026-08-03T06:41:53.707437+00:00
License: CC0 · commercial use OK